Janssen’s Nucynta ER repositioning to ease diabetic peripheral neuropathy

Blog photoIt's interesting how often has become the disclosure of new successful cases of drug repositioning. But is seems that serendipity still plays a major role in that process, as we see pharma approaching it quite differently and none has successfully streamlined drug repositioning.

Janssen's Nucynta ER is the first opioid drug to be approved by the FDA to be used for pain from nerve damage caused by Diabetes. For a drug with $160 million in sales revenue in 2011 and forecasted revenue of $600 million in 2016, this is a great opportunity for Janssen Pharmaceuticals to expand its sales figures considerably, as the new drug will be useful for at least 8 million Americans affected by diabetic peripheral neuropathy.

Read the full article here.

Like Nucynta ER , some other key drug repositioning case studies will be presented at US's World Drug Repositioning Congress this December in DC.

Leave a Reply

Your email address will not be published. Required fields are marked *